{"id":8328,"date":"2024-11-08T10:11:00","date_gmt":"2024-11-08T10:11:00","guid":{"rendered":"https:\/\/www.drfz.de\/news\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/"},"modified":"2025-02-06T10:12:50","modified_gmt":"2025-02-06T10:12:50","slug":"biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert","status":"publish","type":"post","link":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/","title":{"rendered":"Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">A research team led by Ahmed Hegzay, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin and DRFZ, has identified a biomarker that can predict whether anti-integrin therapy with the drug vedolizumab will be effective in patients with chronic inflammatory bowel disease (IBD) such as Crohn\u2019s disease or ulcerative colitis. As therapies for IBD do not work equally well in all patients, this is a step towards the realisation of successful personalised therapy in IBD patients. The results of the study were recently published in the journal&nbsp;<em>Gastroenterology<\/em>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chronic inflammatory bowel disease is caused by uncontrolled activation of immune cells, such as T cells, in the intestine and occurs in relapses, which makes treatment difficult. The drug vedolizumab specifically blocks T cells to prevent them from entering the intestine. However, it is only effective in two thirds of patients, while one third do not benefit from it at all. In order to predict the success of the treatment, the researchers examined patients before and after starting the therapy using cutting edge analysis methods and machine learning. They identified patterns that predict a response to the therapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">One key biomarker, the cell division protein Ki67, proved to be reliable: treatment was often unsuccessful in patients with a high number of Ki67-positive T helper cells in their blood, as these cells have no binding sites for vedolizumab and can continue to migrate into the intestine and cause inflammation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Future studies should confirm the results so that the biomarker can be integrated into clinical routine. In the long term, the aim is to personalised and improve the treatment of chronic inflammatory bowel diseases.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.charite.de\/service\/pressemitteilung\/artikel\/detail\/vorhersage_fuer_behandlungserfolg_bei_chronisch_entzuendlicher_darmerkrankung_moeglich\/\" target=\"_blank\" rel=\"noreferrer noopener\">Link to Charit\u00e9 Press Release<\/a><\/div>\n<\/div>\n\n\n\n  <section     class=\"section grid-heads alignwide\">\n    <div class=\"container container--center\">\n      \n              <div class=\"grid-heads__items grid grid--4\">\n          \n<article\n  id=\"post-3779\" class=\"teaser-head launimation slideBottom  post-3779 head type-head status-publish has-post-thumbnail hentry department-pa-4-translational-rheumatology liaison-charite-gastroenterology-infectiology-and-rheumatology programme-area-tax-programme-area-4 working-group-function-group-leader working-group-tax-inflammatory-mechanisms\">\n  <div class=\"teaser-head__image\">\n          <img decoding=\"async\" loading=\"lazy\" sizes=\"auto, 520px\" src=\"https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/12\/Hegazy_Ahmed-150x100.jpg\" data-src=\"https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/12\/Hegazy_Ahmed-1024x684.jpg\" data-srcset=\"https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/12\/Hegazy_Ahmed-1920x1282.jpg 1920w, https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/12\/Hegazy_Ahmed-1600x1068.jpg 1600w, https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/12\/Hegazy_Ahmed-1366x912.jpg 1366w, https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/12\/Hegazy_Ahmed-1024x684.jpg 1024w, https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/12\/Hegazy_Ahmed-768x513.jpg 768w, https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/12\/Hegazy_Ahmed-550x367.jpg 550w\" class=\"image image--landscape\" alt=\"\"  width=\"1024\"  height=\"684\">      <\/div>\n  <div class=\"teaser-head__header\">\n    <!--    -->    <!--      -->    <!--    -->    <h2 class=\"h6 teaser-head__title launimation slideBottom\">Prof. Dr. med. Dr. rer. nat. Ahmed N. Hegazy<\/h2>\n          <div class=\"teaser-head__role\">\n                          <p class=\"text-label programme_area_function programme_area department\">\n            Programme Area 4, PA 4 \u2013 Translational Rheumatology          <\/p>\n                          <p class=\"text-label working_group_function working_group\">\n            Group leader: Inflammatory Mechanisms          <\/p>\n                          <p\n            class=\"text-label liaison\">Liaison working group with Charit\u00e9 &#8211; Gastroenterology, Infectiology and Rheumatology<\/p>\n              <\/div>\n      <\/div>\n\n      <div class=\"teaser-head__contact\">\n              <p class=\"text-label\"><a href=\"mailto:ahmed.hegazy@charite.de\"\">ahmed.hegazy@charite.de<\/a><\/p>\n          <\/div>\n    <a href=\"https:\/\/www.drfz.de\/en\/koepfe\/ahmed-n-hegazy\/\"\n    aria-describedby=\"post-3779\"\n    title=\"Gehe zum Beitrag\" rel=\"bookmark\"\n    class=\"teaser-head__link button button--small button--arrow button--arrow-link\"><span\n      class=\"visually-hidden\">Prof. Dr. med. Dr. rer. nat. Ahmed N. Hegazy<\/span><\/a>\n<\/article>        <\/div>\n          <\/div>\n  <\/section>\n\n\n\n  <section id=\"block_8f7b537fb5f90bd362ee23924423fa8f\" class=\"section links-list  alignwide \">\n    <div class=\"container container--center\">\n      \n      <div class=\"links-list__items-wrap\">\n        \n<div class=\"links-list__items links-list__items--row \">\n      <div class=\"links-list__item  launimation slideBottom\">\n      \n      <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0016508524055276?via%3Dihub\" target=\"_blank\" class=\"h6 links-list__item-title\">original publication<\/a>\n\n              <span class=\"links-list__item-underline\">Horn V, Cancino CA, Steinheuer LM, Obermayer B, Fritz K, Nguyen AL, Juhran KS, Plattner C, B\u00f6sel D, Oldenburg L, Burns M, Schulz AR, Saliutina M, Mantzivi E, Lissner D, Conrad T, Mashreghi MF, Zundler S, Sonnenberg E, Schumann M, Haag LM, Beule D, Flatz L; TRR241 IBDome Consortium; Trjanoski Z, D&#039;Haens G, Weidinger C, Mei HE, Siegmund B, Thurley K, Hegazy AN. Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin \u03b14\u03b27-Blocking Therapy in Inflammatory Bowel Disease. Gastroenterology. 2024 Sep 28:S0016-5085(24)05527-6. doi: 10.1053\/j.gastro.2024.09.021. Epub ahead of print. PMID: 39343250.<\/span>\n      \n      <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0016508524055276?via%3Dihub\" target=\"_blank\" class=\"links-list__item-link\">\n        <span class=\"button button--arrow button--arrow-nw button--arrow-link\" ><\/span>\n      <\/a>\n    <\/div>\n  <\/div>\n      <\/div>\n    <\/div>\n  <\/section>\n\n","protected":false},"excerpt":{"rendered":"<p>A research team led by Ahmed Hegzay, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin and DRFZ, has identified a biomarker that can predict whether anti-integrin therapy with the\u2026<\/p>\n","protected":false},"author":9,"featured_media":4675,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[291],"tags":[488,441,497],"programme-area-tax":[182],"working-group-tax":[246],"class_list":["post-8328","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publications","tag-ahmed-hegazy-en-en","tag-inflammatory-mechanisms","tag-program-area-4","programme-area-tax-programme-area-4","working-group-tax-inflammatory-mechanisms"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease - DRFZ<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease - DRFZ\" \/>\n<meta property=\"og:description\" content=\"A research team led by Ahmed Hegzay, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin and DRFZ, has identified a biomarker that can predict whether anti-integrin therapy with the\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/\" \/>\n<meta property=\"og:site_name\" content=\"DRFZ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/drfz.de\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-08T10:11:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-06T10:12:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.drfz.de\/wp-content\/uploads\/2025\/02\/2024_11_08_Biomarker-bei-CED_AdobeStock_919141011.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Viet Hoang\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DRFZ_Berlin\" \/>\n<meta name=\"twitter:site\" content=\"@DRFZ_Berlin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Viet Hoang\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/\"},\"author\":{\"name\":\"Viet Hoang\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/person\\\/bfb3defd73223982109dc1eafd951bd3\"},\"headline\":\"Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease\",\"datePublished\":\"2024-11-08T10:11:00+00:00\",\"dateModified\":\"2025-02-06T10:12:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/\"},\"wordCount\":284,\"publisher\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/2024_11_08_Biomarker-bei-CED_AdobeStock_919141011.jpg\",\"keywords\":[\"Ahmed Hegazy\",\"Inflammatory Mechanisms\",\"Program area 4\"],\"articleSection\":[\"Publications\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/\",\"name\":\"Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease - DRFZ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/2024_11_08_Biomarker-bei-CED_AdobeStock_919141011.jpg\",\"datePublished\":\"2024-11-08T10:11:00+00:00\",\"dateModified\":\"2025-02-06T10:12:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/2024_11_08_Biomarker-bei-CED_AdobeStock_919141011.jpg\",\"contentUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/2024_11_08_Biomarker-bei-CED_AdobeStock_919141011.jpg\",\"width\":800,\"height\":450},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/\",\"name\":\"DRFZ\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#organization\",\"name\":\"Deutsches Rheuma-Forschungszentrum\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/drfz-footer-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/drfz-footer-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Deutsches Rheuma-Forschungszentrum\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/drfz.de\\\/\",\"https:\\\/\\\/x.com\\\/DRFZ_Berlin\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/deutsches-rheuma-forschungszentrum-berlin\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCf8nDuqpkWwcmCWmfSTkE3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/person\\\/bfb3defd73223982109dc1eafd951bd3\",\"name\":\"Viet Hoang\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f8b96e1b0aba912be35271142abfbb8039fdd9593cd9d332398b53a8f5b7156e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f8b96e1b0aba912be35271142abfbb8039fdd9593cd9d332398b53a8f5b7156e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f8b96e1b0aba912be35271142abfbb8039fdd9593cd9d332398b53a8f5b7156e?s=96&d=mm&r=g\",\"caption\":\"Viet Hoang\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease - DRFZ","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/","og_locale":"en_US","og_type":"article","og_title":"Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease - DRFZ","og_description":"A research team led by Ahmed Hegzay, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin and DRFZ, has identified a biomarker that can predict whether anti-integrin therapy with the\u2026","og_url":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/","og_site_name":"DRFZ","article_publisher":"https:\/\/www.facebook.com\/drfz.de\/","article_published_time":"2024-11-08T10:11:00+00:00","article_modified_time":"2025-02-06T10:12:50+00:00","og_image":[{"width":800,"height":450,"url":"https:\/\/www.drfz.de\/wp-content\/uploads\/2025\/02\/2024_11_08_Biomarker-bei-CED_AdobeStock_919141011.jpg","type":"image\/jpeg"}],"author":"Viet Hoang","twitter_card":"summary_large_image","twitter_creator":"@DRFZ_Berlin","twitter_site":"@DRFZ_Berlin","twitter_misc":{"Written by":"Viet Hoang","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/#article","isPartOf":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/"},"author":{"name":"Viet Hoang","@id":"https:\/\/www.drfz.de\/en\/#\/schema\/person\/bfb3defd73223982109dc1eafd951bd3"},"headline":"Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease","datePublished":"2024-11-08T10:11:00+00:00","dateModified":"2025-02-06T10:12:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/"},"wordCount":284,"publisher":{"@id":"https:\/\/www.drfz.de\/en\/#organization"},"image":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/#primaryimage"},"thumbnailUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2025\/02\/2024_11_08_Biomarker-bei-CED_AdobeStock_919141011.jpg","keywords":["Ahmed Hegazy","Inflammatory Mechanisms","Program area 4"],"articleSection":["Publications"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/","url":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/","name":"Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease - DRFZ","isPartOf":{"@id":"https:\/\/www.drfz.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/#primaryimage"},"image":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/#primaryimage"},"thumbnailUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2025\/02\/2024_11_08_Biomarker-bei-CED_AdobeStock_919141011.jpg","datePublished":"2024-11-08T10:11:00+00:00","dateModified":"2025-02-06T10:12:50+00:00","breadcrumb":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/#primaryimage","url":"https:\/\/www.drfz.de\/wp-content\/uploads\/2025\/02\/2024_11_08_Biomarker-bei-CED_AdobeStock_919141011.jpg","contentUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2025\/02\/2024_11_08_Biomarker-bei-CED_AdobeStock_919141011.jpg","width":800,"height":450},{"@type":"BreadcrumbList","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/biomarker-fuer-therapieerfolg-bei-chronischen-darmentzuendungen-identifiziert\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.drfz.de\/en\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.drfz.de\/en\/news\/"},{"@type":"ListItem","position":3,"name":"Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease"}]},{"@type":"WebSite","@id":"https:\/\/www.drfz.de\/en\/#website","url":"https:\/\/www.drfz.de\/en\/","name":"DRFZ","description":"","publisher":{"@id":"https:\/\/www.drfz.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.drfz.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.drfz.de\/en\/#organization","name":"Deutsches Rheuma-Forschungszentrum","url":"https:\/\/www.drfz.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.drfz.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/10\/drfz-footer-logo.svg","contentUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/10\/drfz-footer-logo.svg","width":1,"height":1,"caption":"Deutsches Rheuma-Forschungszentrum"},"image":{"@id":"https:\/\/www.drfz.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/drfz.de\/","https:\/\/x.com\/DRFZ_Berlin","https:\/\/www.linkedin.com\/company\/deutsches-rheuma-forschungszentrum-berlin","https:\/\/www.youtube.com\/channel\/UCf8nDuqpkWwcmCWmfSTkE3w"]},{"@type":"Person","@id":"https:\/\/www.drfz.de\/en\/#\/schema\/person\/bfb3defd73223982109dc1eafd951bd3","name":"Viet Hoang","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f8b96e1b0aba912be35271142abfbb8039fdd9593cd9d332398b53a8f5b7156e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f8b96e1b0aba912be35271142abfbb8039fdd9593cd9d332398b53a8f5b7156e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f8b96e1b0aba912be35271142abfbb8039fdd9593cd9d332398b53a8f5b7156e?s=96&d=mm&r=g","caption":"Viet Hoang"}}]}},"_links":{"self":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts\/8328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/comments?post=8328"}],"version-history":[{"count":1,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts\/8328\/revisions"}],"predecessor-version":[{"id":8329,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts\/8328\/revisions\/8329"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/media\/4675"}],"wp:attachment":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/media?parent=8328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/categories?post=8328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/tags?post=8328"},{"taxonomy":"programme-area-tax","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/programme-area-tax?post=8328"},{"taxonomy":"working-group-tax","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/working-group-tax?post=8328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}